Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Neoplasms 46Squamous Cell Carcinoma of Head and Neck 45Head and Neck Neoplasms 35Lung Neoplasms 34Uterine Cervical Neoplasms 27Neoplasm Metastasis 26Unspecified Adult Solid Tumor, Protocol Specific 24Stomach Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 21Pancreatic Neoplasms 19Colorectal Neoplasms 18Cholangiocarcinoma 17Carcinoma, Squamous Cell 17Esophageal Neoplasms 16Breast Neoplasms 15Mesothelioma, Malignant 14Melanoma 13Urinary Bladder Neoplasms 12Mesothelioma 11Fallopian Tube Neoplasms 11Carcinoma, Ovarian Epithelial 11Sarcoma 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Biliary Tract Neoplasms 9Carcinoma 8Triple Negative Breast Neoplasms 7Recurrence 7

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroendocrine Neoplasms × Cisplatin × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡